XML 140 R107.htm IDEA: XBRL DOCUMENT v3.26.1
Schedule of Stock Options Activities (Details)
¥ in Thousands, shares in Thousands
12 Months Ended
Dec. 31, 2025
$ / shares
Dec. 31, 2025
CNY (¥)
shares
Dec. 31, 2024
$ / shares
Dec. 31, 2024
CNY (¥)
shares
Dec. 31, 2023
$ / shares
Dec. 31, 2023
CNY (¥)
shares
Dec. 31, 2022
CNY (¥)
shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]              
Number of Options Outstanding, Total, Outstanding, Beginning balance [1]   1,402   573   7,949  
Weighted Average exercise price, Outstanding, Beginning balance | $ / shares $ 0.1785   $ 0.6675   $ 1.7905    
Weighted average remaining contractual life, Outstanding, Ending balance   8 years 9 months 21 days   9 years 3 months 25 days   9 years 8 months 23 days 4 years 8 months 1 day
Aggregated intrinsic value, Outstanding, Beginning balance | ¥   ¥ 7,990   ¥ 23,775   ¥ 65,572  
Number of Options Outstanding, Total, Replacement [1]       (22)   (7,876)  
Weighted Average exercise price, Replacement | $ / shares     7.3437   1.3119    
Aggregated intrinsic value, Replacement | ¥          
Number of Options Outstanding, Total, Granted [1]   754   899   528  
Weighted Average exercise price, Granted | $ / shares 0.0486   0.1000   0.1000    
Aggregated intrinsic value, Granted | ¥        
Number of Options Outstanding, Total, Forfeited [1]   (24)   (47)   (28)  
Weighted Average exercise price, Forfeited | $ / shares 0.1000   0.9706   8.1954    
Aggregated intrinsic value, Forfeited | ¥        
Number of Options Outstanding, Total, Outstanding, Ending balance [1]   1,984   1,402   573 7,949
Weighted Average exercise price, Outstanding, Ending balance | $ / shares 0.1358   0.1785   0.6675    
Aggregated intrinsic value, Outstanding, Ending balance | ¥   ¥ 10,332   ¥ 7,990   ¥ 23,775 ¥ 65,572
Number of Options Outstanding,Total, Exercisable, Ending balance [1]   1,507   733   295  
Weighted Average exercise price, Exercisable, Ending balance | $ / shares 0.1471   0.2498   $ 1.1978    
Weighted average remaining contractual life, Exercisable, Ending balance   8 years 10 months 9 days   9 years 3 months 7 days   9 years 5 months 23 days  
Aggregated intrinsic value, Exercisable, Ending balance | ¥   ¥ 7,894   ¥ 4,147   ¥ 11,367  
Number of Options Outstanding, Total, Exercised [1]   (148)   (1)      
Number of Options Outstanding, Consultant, Exercised [1]   148   1      
Weighted Average exercise price, Exercised | $ / shares $ 0.1000   $ 0.1000        
Aggregated intrinsic value, Exercised | ¥          
Employees [Member]              
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]              
Number of Options Outstanding, Total, Outstanding, Beginning balance [1]   1,402   573   7,618  
Number of Options Outstanding, Total, Replacement [1]       (22)   (7,545)  
Number of Options Outstanding, Total, Granted [1]   323   899   528  
Number of Options Outstanding, Total, Forfeited [1]   (24)   (47)   (28)  
Number of Options Outstanding, Total, Outstanding, Ending balance [1]   1,553   1,402   573 7,618
Number of Options Outstanding,Total, Exercisable, Ending balance [1]   1,076   733   295  
Number of Options Outstanding, Total, Exercised [1]   (148)   (1)      
Number of Options Outstanding, Consultant, Exercised [1]   148   1      
Consultant [Member]              
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]              
Number of Options Outstanding, Total, Outstanding, Beginning balance [1]       331  
Number of Options Outstanding, Total, Replacement [1]         (331)  
Number of Options Outstanding, Total, Granted [1]   431      
Number of Options Outstanding, Total, Forfeited [1]        
Number of Options Outstanding, Total, Outstanding, Ending balance [1]   431     331
Number of Options Outstanding,Total, Exercisable, Ending balance [1]   431      
Number of Options Outstanding, Total, Exercised [1]          
Number of Options Outstanding, Consultant, Exercised [1]          
[1] Shares outstanding for all periods reflect the adjustment for Reverse Recapitalization (Note 3).